JW-65 是一种具有良好血脑屏障穿透性的 TRPC3 通道选择性抑制剂,可直接结合人源 TRPC3 蛋白并调控钙信号传导以降低癫痫发作易感性,在多种癫痫模型中降低癫痫发作的发生率、严重程度与持续时长,同时延长癫痫发作潜伏期,并可减轻 Aβ 诱导的神经元损伤,是研究癫痫、癫痫性疾病及阿尔茨海默病的重要工具。
产品编号: MS-A72842 纯度: 99.05% CAS No.: 2763378-71-6 分子式: C18H13Cl2F3N4O2 分子量: 445.22
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

JW-65 是一种具有良好血脑屏障穿透性的 TRPC3 通道选择性抑制剂,可直接结合人源 TRPC3 蛋白并调控钙信号传导以降低癫痫发作易感性,在多种癫痫模型中降低癫痫发作的发生率、严重程度与持续时长,同时延长癫痫发作潜伏期,并可减轻 Aβ 诱导的神经元损伤,是研究癫痫、癫痫性疾病及阿尔茨海默病的重要工具。

生物实验数据

生物活性 JW-65 is a selective TRPC3 channel inhibitor with good blood-brain barrier penetration that directly binds human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility, decreases seizure incidence, severity, and duration while prolonging seizure latency in multiple epilepsy models, attenuates Aβ-induced neuronal damage, and serves as an important tool for studying epilepsy, epileptic diseases, and Alzheimer's disease.
IC50 & Target

TRPC3

0.37 μM (IC50)

体外研究
(In Vitro)

JW-65 (0.001-10 μM) 可强效抑制 HEK293 细胞中 hTRPC3 介导的电流,其 IC50 值在无细胞外 Ca2+ 时为 0.37 μM。
JW-65 (10 μM) 是一种相对于 TRP 通道家族其他成员而言对 hTRPC3 具有选择性的抑制剂,在 10 μM 浓度下对 hTRPA1、rTRPV1、rTRPV4 或 hTRPM8 无抑制作用,仅对亲缘关系较近的 hTRPC6 (39%) 和 hTRPC7 (26%) 有部分抑制作用。
JW-65 相较于 Pyr3 (MS-H66553) 表现出显著提升的代谢稳定性,在小鼠、大鼠和人肝微粒体中的半衰期超过 4 h。

体内研究
(In Vivo)

JW-65 (腹腔注射;单次给药,剂量 5-40 mg/kg) 可剂量依赖性降低雄性和雌性 GEPR-3 大鼠的声诱发癫痫发作发生率、潜伏期、持续时间及严重程度,其中雌性大鼠表现出更高的敏感性。
JW-65 (腹腔注射,每日 1 次,连续 5 天),可完全抑制雄性和雌性 GEPR-3 大鼠的声诱发癫痫发作。
JW-65 (腹腔注射,100 mg/kg,连续 2 天每日 1 次,第 3 次给药于实验当日 Pilocarpine (MS-U99376) 注射前 15 分钟) 可显著抑制小鼠中 Pilocarpine 诱导的癫痫持续状态的发生与发展。
JW-65 (100 mg/kg;腹腔注射;癫痫发作 2 期后单次给药) 可缓解 Pilocarpine 诱导的小鼠癫痫持续状态进展,阻止所有接受治疗的小鼠发展为持续性癫痫持续状态,并降低脑电图癫痫发作活动。
JW-65 (20-100 mg/kg;腹腔注射;PTZ 注射前 30 分钟单次给药) 可呈剂量依赖性降低小鼠对 PTZ 诱导癫痫发作的敏感性。

Animal Model: Genetically Epilepsy-Prone Rats (GEPR-3) (adult male and female, 8 weeks old)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.p.; single dose
Result: Reduced seizure duration in males at 5 mg/kg without altering other seizure parameters in either sex.
Dose-dependently decreased WRS and GTCS incidence, prolonged latency, shortened duration, and reduced severity at 10, 20, and 40 mg/kg in both sexes, with stronger effects in females.
Impaired seizure activity most potently at 40 mg/kg, with maximal inhibition of GTCS (89%) in females.
Induced mild neurological side effects only at 40 mg/kg, and was well-tolerated at 5-20 mg/kg.
Animal Model: Genetically Epilepsy-Prone Rats (GEPR-3) (adult male and female, 8 weeks old)
Dosage: 10 mg/kg
Administration: i.p.; daily; 5 consecutive days
Result: Completely suppressed WRS and GTCS incidence, duration, and severity in both sexes at 0.5-4 h after the last treatment; seizure susceptibility recovered to baseline at 24 h.
Markedly prolonged seizure latency in both sexes at 0.5-4 h after the last treatment.
Significantly reduced seizure duration in females but not males at 24 h after the last treatment.
Animal Model: C57BL/6 (young adult male, 8-10 weeks, pilocarpine-induced status epilepticus, pretreated with methylscopolamine and terbutaline prior to pilocarpine injection)
Dosage: 100 mg/kg
Administration: i.p.; once daily for 2 consecutive days, plus a third dose on experiment day 15 minutes before pilocarpine injection
Result: Markedly reduced overall behavioral seizure scores.
Prolonged latencies to Stage 2, 3, and 4 seizures with high statistical significance.
Decreased both average and maximal seizure scores.
Dramatically lowered the incidence of status epilepticus.
Animal Model: C57BL/6 (young adult male, 8-10 weeks, pilocarpine-induced status epilepticus, pretreated with methylscopolamine and terbutaline prior to pilocarpine injection, treatment administered after seizure onset)
Dosage: 100 mg/kg
Administration: i.p.; single dose administered after Stage 2 seizure onset
Result: Reduced overall behavioral seizure scores.
Prolonged latencies to Stage 3 and Stage 4 seizures significantly.
Lowered both average and maximal seizure scores.
Blocked long-lasting status epilepticus in all treated mice.
Elevated survival rate to 88.8% from 53.8% in vehicle controls.
Decreased EEG spike counts time-dependently within 4 hours.
Animal Model: C57BL/6 (young adult male, 8-10 weeks, pentylenetetrazole-induced seizures)
Dosage: 20 mg/kg; 100 mg/kg
Administration: i.p.; single dose 30 minutes before PTZ injection
Result: Lowered the proportion of mice exhibiting myoclonic jerks (MJ) and prolonged MJ latency at 20 mg/kg.
Reduced the incidence of both MJ and GTCS in mice at 100 mg/kg.
Markedly delayed the onset of initial MJ and GTCS at 100 mg/kg, with efficacy similar to phenytoin.
性状 固体
颜色 White to off-white

化学信息

分子量 445.22
分子式 C18H13Cl2F3N4O2
CAS No. 2763378-71-6

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (56.15 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2461 mL11.2304 mL22.4608 mL56.1520 mL
5 mM0.4492 mL2.2461 mL4.4922 mL11.2304 mL
10 mM0.2246 mL1.1230 mL2.2461 mL5.6152 mL
15 mM0.1497 mL0.7487 mL1.4974 mL3.7435 mL
20 mM0.1123 mL0.5615 mL1.1230 mL2.8076 mL
25 mM0.0898 mL0.4492 mL0.8984 mL2.2461 mL
30 mM0.0749 mL0.3743 mL0.7487 mL1.8717 mL
40 mM0.0562 mL0.2808 mL0.5615 mL1.4038 mL
50 mM0.0449 mL0.2246 mL0.4492 mL1.1230 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础